# Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

> **NCT06485713** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- Drug Therapy

## Interventions

- **DRUG:** trifluridine/tipiracil combined with fufuquitinib
- **DRUG:** fufuquitinib
- **DRUG:** Trifluridine/tipiracil

## Key facts

- **NCT ID:** NCT06485713
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485713, "Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06485713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*